These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 14567168)

  • 1. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders].
    Lôo H; Daléry J; Macher JP; Payen A
    Encephale; 2003; 29(2):165-71. PubMed ID: 14567168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders].
    Lôo H; Daléry J; Macher JP; Payen A
    Encephale; 2002; 28(4):356-62. PubMed ID: 12232545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
    Goodwin GM; Emsley R; Rembry S; Rouillon F;
    J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
    Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
    Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.
    Lôo H; Hale A; D'haenen H
    Int Clin Psychopharmacol; 2002 Sep; 17(5):239-47. PubMed ID: 12177586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
    Olié JP; Kasper S
    Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
    Lemoine P; Guilleminault C; Alvarez E
    J Clin Psychiatry; 2007 Nov; 68(11):1723-32. PubMed ID: 18052566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients.
    Quera-Salva MA; Hajak G; Philip P; Montplaisir J; Keufer-Le Gall S; Laredo J; Guilleminault C
    Int Clin Psychopharmacol; 2011 Sep; 26(5):252-62. PubMed ID: 21829106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
    Stein DJ; Ahokas AA; de Bodinat C
    J Clin Psychopharmacol; 2008 Oct; 28(5):561-6. PubMed ID: 18794654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agomelatine: a preliminary review of a new antidepressant.
    Zupancic M; Guilleminault C
    CNS Drugs; 2006; 20(12):981-92. PubMed ID: 17140278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major depressive disorder, anhedonia and agomelatine: an open-label study.
    Di Giannantonio M; Di Iorio G; Guglielmo R; De Berardis D; Conti CM; Acciavatti T; Cornelio M; Martinotti G
    J Biol Regul Homeost Agents; 2011; 25(1):109-14. PubMed ID: 21382280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial.
    Zajecka J; Schatzberg A; Stahl S; Shah A; Caputo A; Post A
    J Clin Psychopharmacol; 2010 Apr; 30(2):135-44. PubMed ID: 20520286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agomelatine: new drug. Adverse effects and no proven efficacy.
    Prescrire Int; 2009 Dec; 18(104):241-5. PubMed ID: 20020562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
    San L; Arranz B
    Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.
    Kennedy SH; Emsley R
    Eur Neuropsychopharmacol; 2006 Feb; 16(2):93-100. PubMed ID: 16249073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
    Lemoine P; Touchon J; Billardon M
    Encephale; 1997; 23(4):290-9. PubMed ID: 9417395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial.
    Corruble E; de Bodinat C; Belaïdi C; Goodwin GM;
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2219-34. PubMed ID: 23823799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Agomelatine: the first "melatoninergic" antidepressant].
    Bánki MC
    Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression.
    Stein DJ; Picarel-Blanchot F; Kennedy SH
    Hum Psychopharmacol; 2013 Mar; 28(2):151-9. PubMed ID: 23532747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.